AI decision layer
for drug development
Biologically grounded AI trusted by industry leaders to de-risk development and increase pipeline confidence
This partnership allows us to leverage our AI-driven technologies for a more comprehensive understanding of cancer biology.
The challenge of immune resistance in cancer treatment requires clinically precise solutions that address not only immune suppression, but also immune exclusion.
We are pleased to enter this partnership with BostonGene, which will enable us to leverage cutting-edge technology to advance our oncology research and development.
Our collaboration with BostonGene has provided in-depth information on patient phenotypes in the Phase I trial.
We partnered with BostonGene in order to validate theorized mechanisms of ADC efficacy and uncover novel biomarkers.
This collaboration will empower us to predict which patients will benefit from treatment helping us design safer, more effective therapies from the start.
De-risking complex clinical development
Proven program outcomes in patient selection, trial risk reduction, and higher-confidence development decisions
Explore more cases
3×
Higher response rate in the enriched cohort
Advanced a stalled Phase 1 asset
Tripled the response rate by selecting the right patients
Blood-based signature turned a 9.3% responder rate into 26.3% — deployable as a simple flow panel for Phase 2 selection.
- Minimally invasive flow testing
- 10-week project delivery
56%
lower CRS rate in the selected cohort
Mitigated toxicity risk in a pivotal trial
Identified high-risk patients before treatment
Blood-only predictor of cytokine release syndrome (CRS) reshaped Phase 2 design — pre identifying high-risk patients and cutting the CRS rate from 43% to 19%.
- Minimally invasive blood testing
- 13-week project delivery
21months
In trial timeline reduction
Accelerated Phase 2 timeline
Enabled biomarker-driven patient selection
A clinical-grade SCLC subtype classifier identified a >$2B revenue opportunity by reducing the trial timeline by 21 months and enabling indication expansion.
- CAP/CLIA assay development
- 16-week project delivery
Mechanism-level intelligence for every phase transition
Uncover efficacy drivers, safety risks, and competitive differentiation to confidently determine where an asset can win, and when to advance, adapt, or stop
Capital at risk
Development phase
Preclinical
FIH / Phase 1
Phase 2
Phase 3
Build translational confidence
Preclinical to First-in-Human (FiH)
- Indication prioritization
- Intervention response modeling
- Translational biomarker strategy
Establish clinical signal
FiH to Phase 1b/2a
- Efficacy & safety signal interpretation
- Responder & risk-group identification
- Go/No-Go decision guidance
De-risk pivotal development
1b/2a to Phase 2b/3
- Biomarker-guided patient selection
- Predictive biomarker validation
- AI-driven trial design optimization
Expand asset potential
Post-approval growth
- Indication expansion
- Combination strategy
- New responder population discovery
-
Preclinical Build translational confidence
Preclinical to First-in-Human (FiH)
- Indication prioritization
- Intervention response modeling
- Translational biomarker strategy
-
FIH / Phase 1 Establish clinical signal
FiH to Phase 1b/2a
- Efficacy & safety signal interpretation
- Responder & risk-group identification
- Go/No-Go decision guidance
-
Phase 2 De-risk pivotal development
1b/2a to Phase 2b/3
- Biomarker-guided patient selection
- Predictive biomarker validation
- AI-driven trial design optimization
-
Phase 3 Expand asset potential
Post-approval growth
- Indication expansion
- Combination strategy
- New responder population discovery
Multimodal data powering biologically grounded AI
BostonGene's integrated laboratory generates unique multimodal data to ground our AI models in tumor and immune biology
Recognized for innovation. Built for partnership.
Translational insights grounded in tumor and immune biology
Nature • October 18, 2023
Clinical trial links oncolytic immunoactivation to survival...
Cancer Cell • May 14, 2024
Comprehensive peripheral blood immunoprofiling...
Cancer Cell • February 29, 2024
Multiomic profiling of follicular lymphoma...
Gastroenterology • May 6, 2024
Transcriptomic-based tumor microenvironment classification...
